V
Vamshi Sarangi
Publications - 9
Citations - 885
Vamshi Sarangi is an academic researcher. The author has contributed to research in topics: Reactogenicity & Randomized controlled trial. The author has an hindex of 6, co-authored 9 publications receiving 286 citations.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
Raches Ella,Krishna Mohan Vadrevu,Harsh Jogdand,Sai Prasad,Siddharth Reddy,Vamshi Sarangi,Brunda Ganneru,Gajanan N. Sapkal,Pragya D Yadav,Priya Abraham,Samiran Panda,Nivedita Gupta,P. Prabhakar Reddy,Savita Verma,Sanjay K Rai,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Venkat Rao,Randeep Guleria,Krishna Murthy Ella,Balram Bhargava +23 more
TL;DR: A double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and immunogenicity of BBV152 at 11 hospitals across India is presented in this article.
Journal ArticleDOI
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Raches Ella,Siddharth Reddy,Harsh Jogdand,Vamshi Sarangi,Brunda Ganneru,Sai Prasad,Dipankar Das,Dugyala Raju,Usha Praturi,Gajanan N. Sapkal,Pragya D Yadav,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Amit Bhate,Sanjay K Rai,Samiran Panda,Priya Abraham,Nivedita Gupta,Krishna Murthy Ella,Balram Bhargava,Krishna Mohan Vadrevu +25 more
TL;DR: In this article, the authors reported interim findings of the phase 2 trial on the immunogenicity and safety of BBV152, with the first dose administered on day 0 and the second dose on day 28.
Journal ArticleDOI
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Raches Ella,Siddarth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: In this article, the authors reported the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.
Posted ContentDOI
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
Raches Ella Mbbs,Siddharth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savitha Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Kumar Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: A double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy, safety, and immunological lot consistency of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum as discussed by the authors.
Posted ContentDOI
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report
Raches Ella,Siddharth Reddy,Harsh Jogdand,Vamshi Sarangi,Brunda Ganneru,Sai Prasad,Dipankar Das,Dugyala Raju,Usha Praturi,Gajanan N. Sapkal,Pragya D Yadav,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Chandra Sekhar Gillurkar,Jitendra Singh Kushwaha,Satyajit Mohapatra,Sanjay K Rai,Amit Bhate,Samiran Panda,Priya Abraham,Nivedita Gupta,Krishna Murthy Ella,Balram Bhargava,Krishna Mohan Vadrevu +25 more
TL;DR: A double-blind, randomised, multicentre, phase 2 clinical trial was conducted in this paper to evaluate the immunogenicity and safety of the SARS-CoV-2 vaccine BBV152.